

**FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

Ad hoc-release pursuant to art. 16 LR

## **SKAN sets price range for IPO at CHF 44 to CHF 55 per share**

- **The IPO consists of a capital increase targeting gross proceeds of approximately CHF 90 million through the placement of up to 2,045,455 new shares (depending on the offer price) and the placement of 2,768,506 existing shares. In addition, there will be an over-allotment option for up to 500,000 existing shares.**
- **The price range has been set at CHF 44 to CHF 55, corresponding to an offer size of CHF 212 million to CHF 242 million in the base Offering and CHF 234 million to CHF 270 million if the over-allotment option is fully exercised.**
- **M&G Investments has committed as a cornerstone investor to a subscription for an aggregate amount of EUR 35.0 million (approx. CHF 37.5 million) in exchange for a guaranteed allocation and subject to customary conditions.**
- **The free float after the IPO is expected to be approximately 50 percent assuming full exercise of the over-allotment option and including pre-IPO shareholders with a stake below 3 percent after completion of the Offering.**
- **The Offering period starts today, 18 October 2021, and is expected to end on 26 October 2021.**
- **The listing and the first day of trading at SIX Swiss Exchange are scheduled for 28 October 2021.**

Allschwil, 18 October 2021 – SKAN Group AG, the global market leader in high-quality isolator systems for aseptic production processes in the (bio)pharmaceutical industry, has defined the terms of its planned IPO at SIX Swiss Exchange.

The transaction comprises a capital increase targeting gross proceeds of approximately CHF 90 million through the placement of up to 2,045,455 new shares (depending on the offer price) and the placement of 2,768,506 existing shares, which will be offered mainly by the current majority shareholder Willy Michel as well as other existing shareholders. Willy Michel will also provide an over-allotment option of up to 500,000 existing shares, resulting in a total Offering of up to 5,313,961 shares (the "Offering"). The over-allotment option may be exercised in whole or in part within 30 days after the first trading day at SIX Swiss Exchange.

The price range for the offered shares has been set at CHF 44 to CHF 55 per share, corresponding to an offer size of CHF 212 million to CHF 242 million, or CHF 234 million to CHF 270 million if the over-allotment option is fully exercised. Assuming an Offer Price at the

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

mid-point of the price range, SKAN Group will achieve a market capitalization of CHF 1,117 million.

If all shares are placed and the over-allotment option is fully exercised, the expected free float of SKAN Group – including the proportion of pre-IPO shareholders with a stake below 3 percent after completion of the Offering – will be approximately 50 percent (lock-ups not considered). The largest shareholders after the IPO will be Willy Michel, the Plattner family and Peter Baumann (SKAN founder).

M&G Investments as asset manager acting for and on behalf of certain funds (the “Cornerstone Investor”), has committed to subscribe for freely tradable shares in the IPO at the final offer price for an aggregate amount of EUR 35.0 million (at current exchange rates corresponding to approximately CHF 37.5 million), in exchange for a guaranteed allocation. The commitment of the Cornerstone Investor is subject to customary conditions.

The Offering consists of (i) a public Offering in Switzerland and (ii) private placements in certain jurisdictions outside the United States and Switzerland pursuant to Regulation S under the U.S. Securities Act of 1933, as amended, and on the basis of the exemptions provided for in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading and the repealing Directive 2003/71/EC and Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, in each case pursuant to applicable securities laws.

The offer and listing prospectus will be published today, 18 October 2021. The bookbuilding process will also start today and is expected to end on 26 October 2021 at 12:00 noon (CEST) for retail investors and at 3:00 p.m. (CEST) for institutional investors. The publication of the offer price and the number of new shares to be issued is scheduled for 27 October 2021, the listing of the shares in accordance with the Swiss Reporting Standard of SIX Swiss Exchange and the start of trading is expected to take place on 28 October 2021. The shares of SKAN Group AG will be delisted from BX Swiss concurrently with the listing on SIX Swiss Exchange and it is currently expected that the last trading day on BX Swiss will be on 27 October 2021.

SKAN Group intends to utilize the net proceeds from the capital increase to finance its growth strategy, in particular for investments in capacity expansion and in new product and service offerings.

A lock-up period of 12 months applies to the company and the members of the management and the Board of Directors who hold shares in SKAN Group AG. In the case of Willy Michel, Thomas Plattner and Peter Baumann, a lock-up period of up to 18 months applies.

Credit Suisse and Berenberg are acting as Joint Global Coordinators and Joint Bookrunners for the planned IPO. KPMG is the independent financial advisor to SKAN Group AG.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

**Pioneer and global market leader in high-quality isolator systems with clear growth strategy and attractive financial profile**

Founded in 1968, SKAN Group is a pioneer in the field of aseptic manufacturing processes for the (bio-)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems which enable medicines to be filled in accordance with strict sterility standards. Innovative solutions, strong process competence and an efficient life-cycle support organisation make SKAN Group an important partner for pharmaceutical and biotech companies, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide.

With its products and services, SKAN Group targets a dynamic market that is driven by fundamental trends. These include the growth of the global (bio-)pharmaceutical industry, the shift towards injectable therapies, the COVID-19-driven expansion of capacity, and the replacement of cleanrooms with isolator systems due to their superiority in terms of sterility and cost. In addition, the market is characterised by high entry barriers and significant production switching costs.

SKAN Group plans to further strengthen its market leadership by investing in its manufacturing capacities and in innovations. In addition, the growth strategy is aimed at expanding the addressable market in the direction of integrated, partially also robot-assisted process systems, the expansion of the service business and the revenues from consumables and, last but not least, digital transformation. These initiatives create the conditions for SKAN Group to continue its growth path, increase the share of recurring revenues and boost the profitability of the business.

SKAN Group achieved average annual net sales growth of 30.5 percent over the past three years. In the 2020 financial year, net sales amounted to CHF 207.3 million and EBITDA to CHF 34.4 million, corresponding to an EBITDA margin of 16.6 percent (figures adjusted for the one-time effect from a discontinued joint venture). In the first half of 2021, order intake increased by 33 percent to CHF 156.8 million compared to the same period of the previous year. The record high order backlog of CHF 220.8 million as of 30 June 2021 together with the solid sales pipeline create good sales visibility for the current and coming financial year.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

### Key data and indicative timetable of the planned IPO

Key data	
Listing	SIX Swiss Exchange (Swiss Reporting Standard)
Ticker	SKAN
Swiss security number	1339601
ISIN	CH0013396012
Share category	Registered shares
Nominal value	CHF 0.01
Price range	CHF 44 to CHF 55
Base Offering	Up to 2,045,455 new shares 2,768,506 existing shares
Over-allotment option (greenshoe)	Up to 500,000 existing shares
Expected number of shares post-IPO	Up to 22,797,485 shares
Indicative timetable	
Publication of Offering and listing prospectus	18 October 2021
Start of bookbuilding	18 October 2021
End of bookbuilding	On or around 26 October 2021, at 12.00 noon (CEST) for retail and private banking orders and at 15.00 (CEST) for institutional orders
Publication of offer price and number of offered shares	On or around 27 October 2021
Listing and first trading day	On or around 28 October 2021
Payment and settlement	On or around 1 November 2021
Last day for the exercise of the over-allotment option	On or around 29 November 2021

### Contacts:

Thomas Balmer, Dynamics Group AG, tba@dynamicsgroup.ch, +41 79 703 87 28

Alexandre Müller, Dynamics Group AG, amu@dynamicsgroup.ch, +41 79 635 64 13

### About SKAN:

Founded in 1968, SKAN is one of the pioneering companies in the specialist areas of clean-room equipment and the construction of isolators for the pharmaceutical industry. Innovative products, customer-specific solutions and an efficient service organization made SKAN a market leader and important partner for industry and research laboratories.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares or other securities. This document is not a prospectus within the meaning of the Swiss Financial Services Act ("**FinSA**") or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. The offer and listing of any securities will be made solely by means of, and on the basis of, a prospectus which is to be approved by the competent review body and published. A decision to invest in securities of SKAN Group AG should be based exclusively on the prospectus published by SKAN Group AG for such purpose. Investors are furthermore advised to consult their bank or financial adviser before making any investment decision.

Statements made in this publication may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", "will", "could" and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them. Forward-looking statements contained in this media release regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Neither SKAN Group AG nor SKAN Holding AG nor any of their respective affiliates is under any obligation, and each such entity expressly disclaims any such obligation, to update, revise or amend any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on any such forward-looking statements, which speak only as of the date of this media release. It should be noted that past performance is not a guide to future performance.

Except as required by applicable law, SKAN Group AG has no intention or obligation to update, keep updated or revise this publication or any parts thereof (including any forward-looking statement) following the date hereof.

This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan, Australia or any jurisdiction into which the same would be unlawful. This announcement does not constitute or form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United States, Canada, Japan, Australia or any jurisdiction in which such an offer or solicitation is unlawful. SKAN Group AG shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom, and no such offer of securities will be made to the public in the United Kingdom, except that offers of securities may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation: (i) to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation; or (ii) in any other circumstances falling within section 86 of the Financial Services and Markets Act 2000 (the "**FSMA**"), provided that no such offer of securities shall require SKAN Group AG to publish a prospectus pursuant to section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

the purposes of this provision, the expression an "offer to the public" in relation to the securities means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase the securities, and the expression "**UK Prospectus Regulation**" means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. In addition, in the United Kingdom, this document is only being distributed to and is only directed at (i) investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"), (ii) high net worth entities falling within article 49 of the Order or (iii) other persons to whom it may lawfully be communicated, (all such persons together being referred to as "**relevant persons**"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

In relation to each member state of the European Economic Area (each a "**Member State**"), no securities have been offered and will be offered to the public in that Member State, except that offers of securities may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: (i) to any legal entity which is a qualified investor as defined under the Prospectus Regulation; or (ii) in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of securities shall require SKAN Group AG to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. For the purposes of this provision, the expression an "**offer to the public**" in relation to the securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase securities, and the expression "**Prospectus Regulation**" means Regulation (EU) 2017/1129.

**Information to Distributors:** Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process by each Manager established in the EEA, which has determined that the Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Managers established in the EEA will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

None of the underwriters or any of their respective subsidiary undertakings, accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy,

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.**

completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. Accordingly, each of the underwriters and the other foregoing persons disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of this announcement and/or any such statement.